Search
Showing results for "Childhood interstitial lung disease "
Here are some of the most common questions about phage, phage therapy and antimicrobial resistance (AMR).
The results of the Kwinana Children's Health Respiratory Study have today been sent to the nearly 600 participating children from almost 500 families
Risk factors for the association of Scedosporium in cases of cystic fibrosis (CF) and its clinical implications are poorly understood
An exciting study is investigating whether a new therapeutic treatment for asthma will protect young sufferers from ongoing lung damage and improve their long-term health outcomes.
We are looking for Aboriginal parents who are passionate about lung health to join the Aboriginal Advisory Committee (AAC) for our Kids Easy Breathing Study (KEBS). Research shows 1 in 5 Aboriginal* bubs in hospital for bronchiolitis (a common viral chest infection) later had serious damage to their lungs. The aim of our study is to find out why Aboriginal bubbies are more likely to develop long-term lung sickness.
This paper reviews American cutaneous leishmaniasis (ACL) immunogenetics in the state of Bahia (BA), northeastern Brazil, highlighting the interacting roles...
We characterised the nasopharyngeal microbiome of these children in comparison to children with rAOM to identify potentially protective bacteria.
A $350,000 Cure4 Cystic Fibrosis grant is set to propel the Wal-yan Respiratory Research Centre’s Phage WA program forward, supercharging its fight against antimicrobial resistant (AMR) lung infections in people with Cystic Fibrosis (CF) using cutting-edge phage therapy.
Mucosal leishmaniasis (ML) follows localized cutaneous leishmaniasis (CL) caused by Leishmania braziliensis.
The P2X7R is highly expressed on the macrophage cell surface, and activation of infected cells by extracellular ATP has been shown to kill intracellular bacte